AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8193880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus Piperacillin (C + P)
Number of subjects: 205
Study 30146645 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional brackets and Nickel titanium wire
Number of subjects: 45
Study 30146645 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon 3mx brackets and Cu‐NiTi wire
Number of subjects: 45
Study 30146645 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional brackets and Cu‐NiTi wire
Number of subjects: 45
Study 28492082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (CT) - resistance and aerobic training, performed three times a week for 24 weeks
Number of subjects: 22
Study 28492082 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study 26282668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic manual rotation
Number of subjects: 416
Study 26282668 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 416
Study 23011539 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor II G20210A
Number of subjects: 104
Study 23011539 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden
Number of subjects: 104
Study 20132529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50‐100 mg/day)
Number of subjects: 46
Study 20132529 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10‐15 mg/day)
Number of subjects: 46
Study 18436341 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone brief intervention (2 sessions)
Number of subjects: 285
Study 18436341 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 285
Study 17132920 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 20 ng/mL
Number of subjects: 117
Study 17132920 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL
Number of subjects: 117
Study 17132920 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL with AST <= 2 ULN
Number of subjects: 117
Study 17132920 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 100 ng/mL with AST > 2 ULN
Number of subjects: 117
Study 17132920 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP) > or = 200 ng/mL with AST > 2 ULN
Number of subjects: 117
Study 14552542 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy in patients with intermittent claudication
Number of subjects: 50
Study 14552542 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy in patients with chronic cardiac failure
Number of subjects: 50
Study 14552542 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus magnetic resonance spectroscopy in patients with varicose veins
Number of subjects: 50
Study 14552542 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 50
Study 14552542 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intermittent claudication
Number of subjects: 50
Study 10791619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaceprol (400 mg t.i.d.)
Number of subjects: 263
Study 10791619 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d.)
Number of subjects: 263
Study 10791619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaceprol
Number of subjects: 263
Study 10791619 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 263
Study 10791619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 263
Study 9348578 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (tegafur and uracil) 400 mg/day for 1 year after surgery
Number of subjects: 0
Study 9348578 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 8476337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 16
Study 8476337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16
Study 8476337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3548984 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (500 to 750 mg/day, twice daily)
Number of subjects: 210
Study 3548984 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (1,600 to 2,400 mg/day, four times daily)
Number of subjects: 210
Study 3548984 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 210
Study 3548984 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 210
Study 30638029 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV genotypes analysis
Number of subjects: 192
Study 29311084 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg relebactam with 500 mg imipenem-cilastatin, given intravenously every 6 h for 5 doses
Number of subjects: 16
Study 26846295 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure pneumoperitoneum (14 mmHg)
Number of subjects: 50
Study 26846295 — intervention group
Group type: COMPARATOR
Intervention: Low pressure pneumoperitoneum (8 mmHg)
Number of subjects: 50
Study 23965522 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 153
Study 23965522 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aldosterone Levels
Number of subjects: 153
Study 23965522 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian Donor
Number of subjects: 153
Study 23965522 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 153
Study 23019005 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI analysis with musical structure manipulation (scrambling method)
Number of subjects: 0
Study 22610770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluency-enhancing therapy
Number of subjects: 30
Study 17645550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized 0.454% SnF(2)/SHMP dentifrice
Number of subjects: 140
Study 17645550 — intervention group
Group type: COMPARATOR
Intervention: Commercially available negative control dentifrice
Number of subjects: 140
Study 16171667 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (single intravenous dose; 4 microg/kg for patients ≤65 years, 3 microg/kg for patients >65 years)
Number of subjects: 50
Study 16171667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study 12855343 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 50 microg/ml (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, and 3 ml)
Number of subjects: 10
Study 12855343 — intervention group
Group type: COMPARATOR
Intervention: Glycerol (2.5, 5, and 10 ml)
Number of subjects: 10
Study 12855343 — intervention group
Group type: COMPARATOR
Intervention: Saline (2.5, 5, and 10 ml)
Number of subjects: 10
Study 10584888 — intervention group
Group type: EXPERIMENTAL
Intervention: High erythrocyte phosphatidylcholine levels of EPA (upper vs lowest quartile)
Number of subjects: 797
Study 10584888 — intervention group
Group type: EXPERIMENTAL
Intervention: High erythrocyte phosphatidylcholine levels of DHA (upper vs lowest quartile)
Number of subjects: 797
Study 9095707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.05 mg/kg followed by succinylcholine 1.5 mg/kg
Number of subjects: 50
Study 9095707 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study 1683981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine with adrenaline (320,000 dilution)
Number of subjects: 80
Study 1683981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine with adrenaline (800,000 dilution)
Number of subjects: 80
Study 1683981 — intervention group
Group type: COMPARATOR
Intervention: Saline (80 ml)
Number of subjects: 80
Study 1683981 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal administration
Number of subjects: 80
Study 7065559 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide, 10 mg orally
Number of subjects: 10
Study 7065559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31952131 — intervention group
Group type: EXPERIMENTAL
Intervention: Three dates daily for 16 weeks
Number of subjects: 100
Study 31952131 — intervention group
Group type: COMPARATOR
Intervention: Control group (avoided date consumption)
Number of subjects: 100
Study 31063573 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-nasal evaporative intra-arrest cooling
Number of subjects: 677
Study 31063573 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 677
Study 29759777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 582
Study 27142792 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 46
Study 27142792 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg + Ezetimibe 10 mg
Number of subjects: 46
Study 27142792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 25128051 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed information about invasive follow-up testing (colonoscopy)
Number of subjects: 631
Study 25128051 — intervention group
Group type: COMPARATOR
Intervention: No information about invasive follow-up testing
Number of subjects: 631
Study 22011409 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance training plus structured exercise counseling (EXE)
Number of subjects: 73
Study 22011409 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone (CON)
Number of subjects: 73
Study 19293069 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP testing (n = 306)
Number of subjects: 612
Study 19293069 — intervention group
Group type: COMPARATOR
Intervention: No testing (n = 306)
Number of subjects: 612
Study 17470850 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX (bolus fluorouracil and leucovorin with oxaliplatin)
Number of subjects: 2492
Study 17470850 — intervention group
Group type: COMPARATOR
Intervention: FULV (bolus fluorouracil and leucovorin)
Number of subjects: 2492
Study 17470850 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX (oxaliplatin)
Number of subjects: 2492
Study 15902475 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal taurolidine lavage
Number of subjects: 27
Study 15902475 — intervention group
Group type: COMPARATOR
Intervention: Saline peritoneal lavage
Number of subjects: 27
Study 12056673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 15 mg
Number of subjects: 6
Study 12056673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 30 mg
Number of subjects: 6
Study 12056673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 45 mg
Number of subjects: 6
Study 12056673 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 10 mg (active control)
Number of subjects: 6
Study 10509322 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 0
Study 10509322 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast irradiation
Number of subjects: 0
Study 10509322 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 7737638 — intervention group
Group type: EXPERIMENTAL
Intervention: EVS + octreotide (100 micrograms three times a day subcutaneously)
Number of subjects: 58
Study 7737638 — intervention group
Group type: COMPARATOR
Intervention: EVS alone
Number of subjects: 58
Study 7737638 — intervention group
Group type: EXPERIMENTAL
Intervention: EVS + octreotide
Number of subjects: 58
Study 2112339 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early nutrition supplementation (VENS) started immediately after admission (4.4 +/- 0.5 h post-injury)
Number of subjects: 20
Study 2112339 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early nutrition supplementation (VENS)
Number of subjects: 20
Study 2112339 — intervention group
Group type: COMPARATOR
Intervention: Control group (supplementation started after 57.7 +/- 2.6 h post-injury)
Number of subjects: 20
Study 2112339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 6461679 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (1 mg/kg)
Number of subjects: 56
Study 6461679 — intervention group
Group type: COMPARATOR
Intervention: Etretinate (1 mg/kg)
Number of subjects: 56
Study 6461679 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 56
Study 6461679 — intervention group
Group type: COMPARATOR
Intervention: Etretinate
Number of subjects: 56
Study 31045769 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT before and after training sessions + PBMT during detraining
Number of subjects: 0
Study 31045769 — intervention group
Group type: COMPARATOR
Intervention: PBMT before and after training sessions + placebo during detraining
Number of subjects: 0
Study 31045769 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after training sessions + PBMT during detraining
Number of subjects: 0
Study 31045769 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after training sessions + placebo during detraining
Number of subjects: 0
Study 27491950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Home Value-Based Purchasing demonstration (intervention)
Number of subjects: 3
Study 26518765 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 biomarkers added to clinical variables
Number of subjects: 8401
Study 26518765 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 biomarkers (including 8 of the 10) added to clinical variables
Number of subjects: 8401
Study 26518765 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 biomarkers (including the 10 CV composite biomarkers) added to clinical variables
Number of subjects: 8401
Study 26518765 — intervention group
Group type: COMPARATOR
Intervention: Clinical variables alone
Number of subjects: 8401
Study 24379581 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially covered self‐expandable metal stent (pcSEMS)
Number of subjects: 85
Study 24379581 — intervention group
Group type: COMPARATOR
Intervention: Plastic stent (PS)
Number of subjects: 85
Study 21358485 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based video decision aid
Number of subjects: 2505
Study 21358485 — intervention group
Group type: COMPARATOR
Intervention: No video decision aid (Control)
Number of subjects: 2505
Study 19142901 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lymphadenectomy
Number of subjects: 0
Study 19142901 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 19142901 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 17786799 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (broad multiphasic screening + normal consultation)
Number of subjects: 2000
Study 17786799 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (broad multiphasic screening + fixed appointments for health consultations)
Number of subjects: 2000
Study 17786799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2000
Study 14615877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study 14615877 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 10678970 — intervention group
Group type: EXPERIMENTAL
Intervention: SPA-TT(1)
Number of subjects: 0
Study 10678970 — intervention group
Group type: EXPERIMENTAL
Intervention: SPA-TT(2)
Number of subjects: 0
Study 9066317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (10 micrograms) plus bupivacaine (2.5 mg) plus epinephrine (0.2 mg)
Number of subjects: 39
Study 9066317 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal sufentanil (10 micrograms) plus bupivacaine (2.5 mg) plus normal saline (control)
Number of subjects: 39
Study 9066317 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 39
Study 9066317 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI group (epinephrine)
Number of subjects: 39
Study 1533168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (S) 4 micrograms/kg
Number of subjects: 20
Study 1533168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-flunitrazepam (SF) 4 micrograms/kg of S and 40 micrograms/kg of flunitrazepam
Number of subjects: 20
Study 3872228 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles with 2x magnification
Number of subjects: 0
Study 31499240 — intervention group
Group type: EXPERIMENTAL
Intervention: AAR + counseling
Number of subjects: 327
Study 31499240 — intervention group
Group type: COMPARATOR
Intervention: AAR + control
Number of subjects: 327
Study 29750549 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity walking (intervention)
Number of subjects: 6
Study 29750549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting interrupted with light-intensity walking (intervention)
Number of subjects: 6
Study 29750549 — intervention group
Group type: COMPARATOR
Intervention: Sitting condition (control)
Number of subjects: 6
Study 27295867 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate (CSPS) toothpaste
Number of subjects: 134
Study 27295867 — intervention group
Group type: COMPARATOR
Intervention: 0% CSPS toothpaste (placebo)
Number of subjects: 134
Study 27295867 — intervention group
Group type: COMPARATOR
Intervention: Commercial fluoride toothpaste 1
Number of subjects: 134
Study 27295867 — intervention group
Group type: COMPARATOR
Intervention: Commercial fluoride toothpaste 2
Number of subjects: 134
Study 26060460 — intervention group
Group type: EXPERIMENTAL
Intervention: Free conjunctival autotransplant (CAT)
Number of subjects: 190
Study 26060460 — intervention group
Group type: COMPARATOR
Intervention: Limbal conjunctival autotransplant (LCAT)
Number of subjects: 190
Study 26060460 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <50 years (young)
Number of subjects: 190
Study 26060460 — intervention group
Group type: EXPERIMENTAL
Intervention: Large pre-operative pterygium (grade ≥3)
Number of subjects: 190
Study 21987279 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable 4‐0 Vicryl Rapide
Number of subjects: 0
Study 21987279 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable 4‐0 Novafil
Number of subjects: 0
Study 20433999 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin nadroparin
Number of subjects: 0
Study 20433999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19229379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketoprofen (300 mg)
Number of subjects: 60
Study 19229379 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (4 g)
Number of subjects: 60
Study 19229379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15993627 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal interval and force (600 ms intervals, 12 N force)
Number of subjects: 13
Study 15993627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating interval and force (400, 800 ms intervals, 8, 16 N forces)
Number of subjects: 13
Study 15993627 — intervention group
Group type: COMPARATOR
Intervention: Alternating interval
Number of subjects: 13
Study 12867249 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 12867249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10826908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 30
Study 10826908 — intervention group
Group type: COMPARATOR
Intervention: Aztreonam
Number of subjects: 30
Study 8682521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-training, low workload
Number of subjects: 80
Study 8682521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-training, high workload
Number of subjects: 80
Study 8682521 — intervention group
Group type: COMPARATOR
Intervention: No cross-training, low workload
Number of subjects: 80
Study 8682521 — intervention group
Group type: COMPARATOR
Intervention: No cross-training, high workload
Number of subjects: 80
Study 1832372 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms)
Number of subjects: 53
Study 1832372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 53
Study 1832372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (2 mg)
Number of subjects: 53
Study 1832372 — intervention group
Group type: COMPARATOR
Intervention: Aerosol pentamidine (60 mg)
Number of subjects: 53
Study 463806 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural orange juice (80 mg of ascorbic acid daily)
Number of subjects: 362
Study 463806 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic orange juice (80 mg of ascorbic acid daily)
Number of subjects: 362
Study 463806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 30621513 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL‐RAR
Number of subjects: 40
Study 30621513 — intervention group
Group type: COMPARATOR
Intervention: EH
Number of subjects: 40
Study 27426042 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 54
Study 27426042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated LLLT applications)
Number of subjects: 54
Study 25891297 — intervention group
Group type: EXPERIMENTAL
Intervention: POST-RENAL study participants
Number of subjects: 282
Study 25891297 — intervention group
Group type: EXPERIMENTAL
Intervention: POST-RENAL study participants after age and sex matching
Number of subjects: 282
Study 23450052 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women with lower insulin sensitivity index (Si)
Number of subjects: 28
Study 23450052 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women
Number of subjects: 28
Study 23450052 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 28
Study 21684088 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 109
Study 21684088 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 109
Study 21684088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MDFT and CBT
Number of subjects: 109
Study 21684088 — intervention group
Group type: EXPERIMENTAL
Intervention: MDFT
Number of subjects: 109